PRPH (ProPhase Labs) FCF Margin %: -1,063.39% (As of Dec. 2025)


What is ProPhase Labs FCF Margin %?

ProPhase Labs PRPH -4.61% FCF Margin % is -1,063.39% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, ProPhase Labs ranks worse than 84.8% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. ProPhase Labs's Free Cash Flow for the three months ended in Dec. 2025 was $-8.34 Mil. ProPhase Labs's Revenue for the three months ended in Dec. 2025 was $0.78 Mil. Therefore, ProPhase Labs's FCF Margin % for the quarter that ended in Dec. 2025 was -1,063.39%.

As of today, ProPhase Labs's current FCF Yield % is -653.41%.

The historical rank and industry rank for ProPhase Labs's FCF Margin % or its related term are showing as below:

PRPH' s FCF Margin % Range Over the Past 10 Years
Min: -272.44   Med: -28.1   Max: 20.08
Current: -192.04

During the past 13 years, the highest FCF Margin % of ProPhase Labs was 20.08%. The lowest was -272.44%. And the median was -28.10%.

PRPH's FCF Margin % is ranked worse than
84.8% of 204 companies
in the Medical Diagnostics & Research industry
Industry Median: -1.845 vs PRPH: -192.04

ProPhase Labs FCF Margin % Related Terms

ProPhase Labs FCF Margin % Historical Data

* Premium members only.

The historical data trend for ProPhase Labs's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProPhase Labs FCF Margin % Chart

ProPhase Labs Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -22.58 20.08 -39.94 -272.44 -192.04

ProPhase Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -238.15 -236.27 -19.81 410.08 -1,063.39

PRPH vs NSTM, IDTA, IVRO: FCF Margin % Comparison

For the Diagnostics & Research subindustry, ProPhase Labs's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProPhase Labs FCF Margin % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's FCF Margin % distribution charts can be found below:

* The bar in red indicates where ProPhase Labs's FCF Margin % falls into.


ProPhase Labs FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

ProPhase Labs's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-8.344/4.345
=-192.04 %

ProPhase Labs's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-8.337/0.784
=-1,063.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -1,063.39% mean?
ProPhase Labs (PRPH) has a FCF Margin % of -1,063.39% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on ProPhase Labs and its competitors. According to the industry distribution chart, ProPhase Labs ranks #173 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 84.8%.
Is ProPhase Labs' FCF Margin % too high?
ProPhase Labs' current FCF Margin % is -1,063.39%. Based on the distribution chart, ProPhase Labs ranks #173 out of 204 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does ProPhase Labs' FCF Margin % compare to NSTM and IDTA?
According to the Medical Diagnostics & Research industry distribution chart, ProPhase Labs ranks #173 out of 204 companies for FCF Margin %. This places ProPhase Labs in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on ProPhase Labs and its competitors. ProPhase Labs's current FCF Margin % is -1,063.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.65, compared to a current price of $0.09 — trading 86% below its estimated fair value. The current FCF Margin % is -1,063.39%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current FCF Margin % is -1,063.39% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProPhase Labs Business Description

Address 626 RXR Plaza, 6th Floor, Uniondale, NY, USA, 11556
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.